Metabolon to Discover, Validate Biomarkers for Takeda | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metabolon said today it is using its metabolomic technology to discover therapeutic targets and biomarkers under a collaboration with Takeda Pharmaceutical.

Under the multi-year deal, Metabolon will apply its analytical platform and software to discover and validate targets and to identify novel pharmacodynamic biomarkers for translation into the clinic.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.